ORIGINAL RESEARCH article
Front. Neurol.
Sec. Stroke
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1660604
Somatic Mutations in Angiogenesis-Related Pathways and RNA Polymerase II Activity in Sporadic Brain Arteriovenous Malformations
Provisionally accepted- 1Neurosurgery Department, Hospital Clinico San Carlos, Madrid, Spain
- 2Instituto de Investigacion Sanitaria Hospital Clinico San Carlos, Madrid, Spain
- 3Hospital Clinico San Carlos Laboratorio de Oncologia Molecular, Madrid, Spain
- 4Pathology Department, Hospital Clinico San Carlos, Madrid, Spain
- 5Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
- 6Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Sporadic brain arteriovenous malformations (bAVMs) are rare vascular anomalies characterized by abnormal angiogenesis and direct arteriovenous shunting. While the VEGF pathway is well studied, the genetic landscape contributing to angiogenic dysregulation remains poorly defined. We aimed to characterize the mutational profile of resected bAVMs using a pan-cancer next-generation sequencing panel, with particular focus on angiogenesis-associated pathways and RNA Polymerase II activity. Methods: A descriptive analysis of clinical and molecular characteristics was conducted In formalin-fixed, paraffin-embedded tissue from the bAVM nidus. DNA was extracted and sequenced using the Oncomine Tumor Mutational Load Assay, covering 409 cancer-related genes. Variants were filtered for pathogenicity, allele frequency, and functional relevance. Results: Thirteen sporadic bAVMs were retrospectively analyzed. Twelve pathogenic variants were detected in 7/13 (54%) patients , with variant allele frequencies ranging from 3.61% to 50.61%. Most mutations clustered within angiogenesis-related pathways (PI3K/AKT/mTOR, RAS/MAPK), DNA repair mechanisms, and transcriptional regulators of RNA Polymerase II. Notably, six mutations involved genes with known functional links to RNA Pol II activity. These findings suggest a converging role for transcriptional dysregulation and vascular remodeling in bAVM pathogenesis. Conclusions: This study proposes a novel hypothesis implicating RNA Polymerase II-mediated transcription in the aberrant angiogenesis of bAVMs. While KRAS mutations were detected at low frequency and allele burden, other genetic alterations in DNA repair and transcriptional machinery may drive or sustain vascular instability. Further functional validation is warranted to clarify their pathogenic role and therapeutic potential. Keywords: brain arteriovenous malformation; angiogenesis; somatic mutation; RNA Polymerase II; PI3K pathway; DNA repair; next-generation sequencing.
Keywords: Brain arteriovenous malformation, Angiogenesis, somatic mutation, RNA Polymerase II, PI3K pathway, DNA Repair, Next-generation sequencing, Intracranial Arteriovenous Malformations
Received: 06 Jul 2025; Accepted: 03 Sep 2025.
Copyright: © 2025 PÉREZ ALFAYATE, García-Barberán, Casado-Fariñas, Hernández-Martínez, Gomez del Pulgar, Castaño-Montoya, Pérez Segura and Cabezas-Camarero. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: REBECA PÉREZ ALFAYATE, Neurosurgery Department, Hospital Clinico San Carlos, Madrid, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.